Patents by Inventor Janet M. Leeds
Janet M. Leeds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210017522Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: August 10, 2020Publication date: January 21, 2021Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Patent number: 10738307Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: October 5, 2017Date of Patent: August 11, 2020Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Publication number: 20180273945Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: October 5, 2017Publication date: September 27, 2018Applicants: Ionis Pharmaceuticals, Inc., CHDI Foundation, Inc.Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Publication number: 20160053256Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: May 11, 2015Publication date: February 25, 2016Applicants: CHDI FOUNDATION INC., ISIS PHARMACEUTICALS, INC.Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
-
Patent number: 9057066Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: December 7, 2012Date of Patent: June 16, 2015Assignees: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
-
Patent number: 7807653Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: GrantFiled: June 14, 2007Date of Patent: October 5, 2010Assignee: Biota Scientific Management Pty LtdInventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
-
Publication number: 20100069472Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: November 13, 2009Publication date: March 18, 2010Applicant: Isis Pharmaceuticals, Inc.Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
-
Patent number: 7598230Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: GrantFiled: June 14, 2007Date of Patent: October 6, 2009Assignee: Biota Scientific Management Pty LtdInventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
-
Patent number: 7285658Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: GrantFiled: February 28, 2003Date of Patent: October 23, 2007Assignee: Biota, Inc.Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
-
Publication number: 20040059104Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: ApplicationFiled: February 28, 2003Publication date: March 25, 2004Inventors: Phillip Dan Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
-
Publication number: 20040023901Abstract: The present invention relates to novel nucleoside 5′-monophosphate mimics, which contain novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, anticancer, and immunomodulatory agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: ApplicationFiled: February 28, 2003Publication date: February 5, 2004Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Vasanthankumar Rajappan, Kandasamy Sakthivel, Kathleen D. Tucker, Jennifer L. Brooks, Janet M. Leeds, Maria Eugenia Ariza, Patrick C. Fagan
-
Patent number: 6355438Abstract: Methods and processes for quantitating the amount of oligonucleotide in a sample of bodily fluid and/or extract are provided. The methods and processes provided allow for the detection and/or localization of oligonucleotides for therapeutic and/or pharmacokinetic purposes by providing a highly sensitive assay that takes advantage of enzymes which recognize specific nucleic acid conformations and structures.Type: GrantFiled: November 10, 2000Date of Patent: March 12, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brenda F. Baker, Zhengrong Yu, Janet M. Leeds
-
Patent number: 6127124Abstract: Methods for the determination of nuclease stability of an oligomeric compound and its deletion sequences by capillary gel electrophoresis using laser-induced fluorescence detection (LIF CGE) are provided. Fluorescently labeled oligomeric compounds are treated with one or more agents having nuclease activity resulting in an assay mixture of the original oligomeric compound and its deletion sequences. A diluted aliquot taken directly from the assay mixture is analyzed using LIF CGE. Results of the assay yield quantitative concentrations of the oligomeric compound and each of the deletion sequences. In further embodiments, the invention provides methods for determining the relative binding affinity of one or more oligomeric compounds for a substrate having nuclease activity, and methods for determining the nuclease activity of an enzyme.Type: GrantFiled: January 20, 1999Date of Patent: October 3, 2000Assignee: Isis Pharmaceuticals, Inc.Inventors: Janet M. Leeds, Lendell L. Cummins